Gilead Sciences GILD
US equityMarket cap rank #82Drug Manufacturers - GeneralCAR-T TherapyInfectious DiseaseCancer Research
$166.89 −$0.68 (-0.41%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $166.89 0.00%
Open$164.11
Prev close$167.57
Day range$164.00 – $169.06
Volume5.82M
Market cap$207.00B
P/E (TTM)–
Dividend yield1.95%
Earnings
Average move on report day±3.7%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+8.3%
Worst reaction-4.2%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | After Market | ±4.9% | +3.06% | Within range |
| 2026/Q2 | 4 Aug 2026 | After Market | ±5.0% | -2.58% | Within range |
| 2026/Q1 | 7 May 2026 | After Market | ±5.5% | -2.04% | Within range |
| 2025/Q4 | 10 Feb 2026 | After Market | ±5.2% | +5.82% | Bigger than priced |
| 2025/Q3 | 30 Oct 2025 | After Market | ±6.7% | +1.14% | Within range |
| 2025/Q2 | 7 Aug 2025 | After Market | ±7.0% | +8.28% | Bigger than priced |
| 2025/Q1 | 24 Apr 2025 | After Market | ±5.6% | -2.81% | Within range |
| 2024/Q4 | 11 Feb 2025 | None | ±4.7% | +7.46% | Bigger than priced |
| 2024/Q3 | 6 Nov 2024 | After Market | ±4.0% | +6.77% | Bigger than priced |
| 2024/Q2 | 8 Aug 2024 | After Market | ±5.3% | -2.55% | Within range |
| 2024/Q1 | 25 Apr 2024 | After Market | ±4.6% | +0.23% | Within range |
| 2023/Q4 | 6 Feb 2024 | After Market | ±4.0% | -4.25% | Bigger than priced |
| 2023/Q3 | 7 Nov 2023 | After Market | ±3.8% | -3.36% | Within range |
| 2023/Q2 | 3 Aug 2023 | After Market | ±4.3% | +4.17% | Within range |
| 2023/Q1 | 27 Apr 2023 | After Market | ±4.5% | -1.60% | Within range |
| 2022/Q4 | 2 Feb 2023 | After Market | ±5.2% | +3.82% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$8.30B+6.8% YoY
Operating profit$3.48B-0.5% YoY
Net profit$2.43B-20.4% YoY
Diluted EPS$1.94-20.2% YoY
Free cash flow$4.80B+21.1% YoY
Operating cash flow$5.04B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin79.9%
Operating margin37.8%
Net margin-12.5%
Return on equity-22.3%
Return on assets-7.0%
Return on invested capital-8.0%
Current ratio1.38
Liabilities / assets74.8%
Cash & investments$6.44B
Total debt$26.23B
Net cash (debt)-$19.79B
Free cash flow / sales44.5%
No comments yet — be the first to weigh in on GILD.
Sign in to join the discussion.